Literature DB >> 18082492

Recovery of normal ventricular function in patients with dilated cardiomyopathy: predictors of an increasingly prevalent clinical event.

Philip F Binkley1, Amanda Lesinski, Jeanette Pohorence Ferguson, Patricia S Hatton, Laura Yamokoski, Sheetal Hardikar, Glen E Cooke, Carl V Leier.   

Abstract

BACKGROUND: This investigation was designed to identify clinical variables associated with recovery of normal ventricular function in patients with dilated cardiomyopathy treated with medical therapy. Recovery of normal ventricular function with medical treatment of patients with dilated cardiomyopathy is observed with increasing frequency. However, the clinical variables associated with such dramatic improvement of ventricular performance are poorly defined.
METHODS: Fifty-three patients with dilated cardiomyopathy and reduced ejection fractions who achieved an increase in ejection fraction to > or = 40% with medical therapy were identified during follow-up in a dedicated heart failure clinic. A cohort of patients frequency-matched on baseline ejection fraction who did not recover ventricular systolic function to this magnitude constituted the control group. Clinical variables characterizing the 2 groups were compared by univariable analysis. Variables that significantly differed between the 2 groups were entered in a stepwise logistic regression analysis to identify factors independently associated with recovery of ejection fraction to > or = 40%.
RESULTS: In the final logistic regression model, QRS duration, sex, etiology of cardiomyopathy, diabetes, and systolic blood pressure were significantly associated with improvement of ejection fraction to > or = 40%.
CONCLUSIONS: Five clinical variables that are independently associated with improvement of left ventricular ejection fraction to normal or near-normal values with medical therapy alone were identified by this modeling process. These variables may be used to discriminate between patients in whom ventricular function will normalize with medical therapy alone and those who will require more aggressive pharmacologic or device therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18082492     DOI: 10.1016/j.ahj.2007.08.010

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  16 in total

1.  Associations between scar characteristics by cardiac magnetic resonance and changes in left ventricular ejection fraction in primary prevention defibrillator recipients.

Authors:  Yiyi Zhang; Eliseo Guallar; Robert G Weiss; Michael Stillabower; Gary Gerstenblith; Gordon F Tomaselli; Katherine C Wu
Journal:  Heart Rhythm       Date:  2016-04-19       Impact factor: 6.343

2.  Predictors and implications of early left ventricular ejection fraction improvement in new-onset idiopathic nonischemic cardiomyopathy with narrow QRS complex: A NEOLITH substudy.

Authors:  Norman C Wang; Evan C Adelstein; Sandeep K Jain; G Stuart Mendenhall; Alaa A Shalaby; Andrew H Voigt; Samir Saba
Journal:  Ann Noninvasive Electrocardiol       Date:  2017-05-12       Impact factor: 1.468

3.  Importance of baseline heart rate as a predictor of cardiac functional recovery in newly diagnosed heart failure with reduced ejection fraction.

Authors:  Ali Valika; Kim Paprockas; Dana Villines; Maria Rosa Costanzo
Journal:  Clin Cardiol       Date:  2018-05-14       Impact factor: 2.882

4.  Association of Genetic Polymorphisms in the Beta-1 Adrenergic Receptor with Recovery of Left Ventricular Ejection Fraction in Patients with Heart Failure.

Authors:  Jasmine A Luzum; Joseph D English; Umair S Ahmad; Jessie W Sun; Benjamin D Canan; Wolfgang Sadee; Joseph P Kitzmiller; Philip F Binkley
Journal:  J Cardiovasc Transl Res       Date:  2019-02-12       Impact factor: 4.132

5.  National experience with long-term use of the wearable cardioverter defibrillator in patients with cardiomyopathy.

Authors:  Madhab Lamichhane; Joseph C Gardiner; Nicole R Bianco; Steven J Szymkiewicz; Ranjan K Thakur
Journal:  J Interv Card Electrophysiol       Date:  2016-10-17       Impact factor: 1.900

6.  Changes in Follow-Up Left Ventricular Ejection Fraction Associated With Outcomes in Primary Prevention Implantable Cardioverter-Defibrillator and Cardiac Resynchronization Therapy Device Recipients.

Authors:  Yiyi Zhang; Eliseo Guallar; Elena Blasco-Colmenares; Barbara Butcher; Sanaz Norgard; Victor Nauffal; Joseph E Marine; Zayd Eldadah; Timm Dickfeld; Kenneth A Ellenbogen; Gordon F Tomaselli; Alan Cheng
Journal:  J Am Coll Cardiol       Date:  2015-08-04       Impact factor: 24.094

7.  Cardiac matrix remodeling following intracoronary cell transplantation in dilated cardiomyopathic rabbits.

Authors:  Bo Jin; Xin-Ping Luo; Huan-Chun Ni; Yong Li; Hai-Ming Shi
Journal:  Mol Biol Rep       Date:  2009-10-11       Impact factor: 2.316

8.  Wearable defibrillator use in heart failure (WIF): results of a prospective registry.

Authors:  Andrew C Kao; Steven W Krause; Rajiv Handa; Darshak Karia; Guillermo Reyes; Nicole R Bianco; Steven J Szymkiewicz
Journal:  BMC Cardiovasc Disord       Date:  2012-12-12       Impact factor: 2.298

Review 9.  Left ventricular reverse remodelling and its predictors in non-ischaemic cardiomyopathy.

Authors:  Tomas Hnat; Josef Veselka; Jakub Honek
Journal:  ESC Heart Fail       Date:  2022-04-18

10.  Prediction of left ventricular reverse remodeling after therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and β blockers in patients with idiopathic dilated cardiomyopathy.

Authors:  Yoshihisa Matsumura; Eri Hoshikawa-Nagai; Toru Kubo; Naohito Yamasaki; Hiroaki Kitaoka; Jun Takata; Yoshinori Doi; Tetsuro Sugiura
Journal:  Cardiovasc Ultrasound       Date:  2015-03-25       Impact factor: 2.062

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.